Impact of Q141K on the Transport of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by ABCG2

Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer

(2016) Debby D. Wang et al.   Molecular BioSystems

Association Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug Reaction

(2016) Siew-Kee Low et al.   PLoS One

Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?

(2015) Bruce K. Birmingham et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

ABCG2 Localizes to the Nucleus and Modulates CDH1 Expression in Lung Cancer Cells

(2015) Shu-Ching Liang et al.   NEOPLASIA

Sunitinib-induced severe toxicities in a Japanese patient with the ABCG2 421 AA genotype

(2015) Yuji Miura et al.   BMC CANCER

Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells

(2014) Petr Kosztyu et al.   CHEMICO-BIOLOGICAL INTERACTIONS

Gefitinib Enhances the Antitumor Activity of CPT-11 in vitro and in vivo by Inhibiting ABCG2 but Not ABCB1: A New Clue to Circumvent Gastrointestinal Toxicity Risk

(2014) Yutaka Inoue et al.   CHEMOTHERAPY

Ethnic Differences in ATP-binding Cassette Transporter, Sub-family G, Member 2 (ABCG2/BCRP): Genotype Combinations and Estimated Functions

(2014) Masayuki Sakiyama et al.   Drug Metabolism and Pharmacokinetics

Functional Polymorphisms of the ABCG2 Gene Are Associated with Gout Disease in the Chinese Han Male Population

(2014) Danqiu Zhou et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699)

(2014) Selvi Durmus et al.   PHARMACEUTICAL RESEARCH

Hes1 is involved in the self-renewal and tumourigenicity of stem-like cancer cells in colon cancer

(2014) Fei Gao et al.   Scientific Reports

ABCG2 is associated with HER-2 Expression, lymph node metastasis and clinical stage in breast invasive ductal carcinoma

(2011) Lei Xiang et al.   Diagnostic Pathology

Elevated BCRP/ABCG2 Expression Confers Acquired Resistance to Gefitinib in Wild-Type EGFR-Expressing Cells

(2011) Yun-Ju Chen et al.   PLoS One

Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia

(2010) Naoto Takahashi et al.   JOURNAL OF HUMAN GENETICS

The rs2231142 variant of the ABCG2 gene is associated with uric acid levels and gout among Japanese people

(2010) K. Yamagishi et al.   RHEUMATOLOGY

Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib

(2009) C Lemos et al.   BRITISH JOURNAL OF CANCER

Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties

(2009) C Hegedűs et al.   BRITISH JOURNAL OF PHARMACOLOGY

The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance

(2009) Chen   ONCOLOGY REPORTS

Different effects of theABCG2c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin

(2009) Jenni E Keskitalo et al.   PHARMACOGENOMICS

Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib Toxicity

(2008) Charles M. Rudin et al.   JOURNAL OF CLINICAL ONCOLOGY

Major SNP (Q141K) Variant of Human ABC Transporter ABCG2 Undergoes Lysosomal and Proteasomal Degradations

(2008) Tomoka Furukawa et al.   PHARMACEUTICAL RESEARCH